STOCK TITAN
  1. Home
  2. News
  3. MRK

Merck & Co., Inc. - MRK STOCK NEWS

Welcome to our dedicated page for Merck & Co. news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co. stock.

Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is a renowned American multinational pharmaceutical company headquartered in Rahway, New Jersey. Originally the American arm of Germany's Merck Group founded in 1668, Merck has established itself as a global leader in pharmaceuticals and vaccines.

Merck's core business is the development and manufacturing of medications and vaccines spanning several therapeutic areas such as cardiometabolic diseases, cancer, and infections. The company's immuno-oncology platform, particularly strong in cancer treatment, is a significant revenue driver. The firm’s oncology portfolio includes groundbreaking immunotherapies like KEYTRUDA, designed to treat melanoma and other cancers. KEYTRUDA, in combination with other therapies, has shown promising results in reducing cancer recurrence and improving survival rates.

Merck also boasts a robust vaccine business, offering vaccines for pediatric diseases and human papillomavirus (HPV). Their commitment to public health extends to Merck for Mothers, an initiative aimed at improving maternal health globally. In 2024, Merck surpassed its goal early by reaching over 30 million women with programs promoting safe, high-quality maternal care.

The company's animal health division is another sector of its diverse operations, providing solutions to improve animal health and productivity.

From a geographical perspective, nearly half of Merck's sales are generated in the United States. Financially, Merck maintains a solid position with ongoing investments in research and development to fuel innovation. The company is actively engaged in numerous partnerships and collaborative research initiatives to accelerate the development of new therapies.

Merck’s mission is rooted in scientific excellence and an unwavering commitment to improving lives. The company continues to invest in leading-edge research, with over 2,250 ongoing clinical trials, including more than 1,600 trials evaluating combination regimens. This dedication underpins Merck's strategy to address complex health challenges and advance global health.

News

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Rhea-AI Summary
Merck's supplemental Biologics License Application for KEYTRUDA in combination with radiotherapy and chemotherapy for cervical cancer has been accepted for priority review by the FDA. If approved, this would be Merck's third indication in cervical cancer and first in an earlier stage of the disease. The FDA has set a target action date of January 20, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
none
-
News

FDA Accepts for Priority Review Merck’s Supplemental New Drug Application for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

Rhea-AI Summary
Merck's supplemental new drug application for WELIREG, an oral HIF-2α inhibitor, has been accepted by the FDA for the treatment of advanced renal cell carcinoma (RCC) following previous therapies. The application has been granted priority review, and the FDA has set a target action date of January 17, 2024. Data from the LITESPARK-005 trial showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to everolimus, as well as a significant improvement in objective response rate (ORR). WELIREG is currently approved for the treatment of VHL disease. This development program includes four Phase 3 trials in RCC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
clinical trial
-
News

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy

Rhea-AI Summary
Merck's anti-PD-1 therapy, KEYTRUDA, receives positive opinion for adjuvant treatment of NSCLC in Europe
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
none
News

Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)

Rhea-AI Summary
Merck presents new analyses of sotatercept for the treatment of pulmonary arterial hypertension (PAH) at ERS International Congress 2023. Exploratory analysis shows that treatment with sotatercept improves right heart size and function. Primary efficacy results from the STELLAR trial demonstrate significant improvement in 6-minute walk distance. SOTERIA study shows long-term safety and efficacy of sotatercept. Applications for regulatory approval of sotatercept have been submitted. Positive potential for sotatercept to transform the treatment of PAH.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
none
-
News

European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older

Rhea-AI Summary
Merck's ERVEBO receives expanded approval from the European Commission for immunization against Ebola Virus Disease caused by Zaire ebolavirus in individuals 1 year of age or older. The vaccine was previously approved for use in individuals 18 years of age or older. Merck has also established a global Ebola vaccine stockpile with UNICEF to support future outbreak preparedness and response efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
none
-
News

Long-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL®9 Published in Pediatrics

Rhea-AI Summary
New 10-year data on GARDASIL 9 vaccine shows no cases of certain HPV-related diseases in boys and girls vaccinated at ages 9-15 years. Antibody responses remained strong at 10 years. No serious adverse events reported.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
none
News

Merck to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Rhea-AI Summary
Merck executives to participate in fireside chat at Morgan Stanley conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
conferences
-
News

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)

Rhea-AI Summary
Merck's KEYTRUDA receives EU approval for first-line treatment of HER2-positive gastric cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
none
-
News

Merck to Participate in the Citi 18th Annual BioPharma Conference

Rhea-AI Summary
Merck's Dr. Marjorie Green to speak at Citi BioPharma Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
conferences
News

Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616

Rhea-AI Summary
Merck initiates Phase 3 clinical program for MK-0616, an oral PCSK9 inhibitor, for the treatment of hypercholesterolemia. Phase 2b results showed significant LDL cholesterol reduction. Program plans to enroll approximately 17,000 participants across three global studies. Positive potential for MK-0616 to provide an important option for patients. No oral PCSK9 inhibitors currently available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
clinical trial

FAQ

What is the current stock price of Merck & Co. (MRK)?

The current stock price of Merck & Co. (MRK) is $101.62 as of November 26, 2024.

What is the market cap of Merck & Co. (MRK)?

The market cap of Merck & Co. (MRK) is approximately 254.7B.

What are the main therapeutic areas Merck focuses on?

Merck focuses on several therapeutic areas including cardiometabolic diseases, cancer, and infections. They also have a significant vaccine business and an animal health division.

What is Merck for Mothers?

Merck for Mothers is Merck’s global initiative dedicated to improving maternal health. The program has reached over 30 million women with initiatives that promote safe, high-quality care during pregnancy and childbirth.

What are some of Merck’s key products in oncology?

Merck's oncology portfolio includes KEYTRUDA, an immunotherapy used to treat various cancers, including melanoma. KEYTRUDA has shown significant benefits when used in combination with other therapies.

How significant is Merck’s vaccine business?

Merck has a substantial vaccine business, offering vaccines for pediatric diseases and human papillomavirus (HPV). Their vaccines portfolio is a major contributor to their public health impact.

Where is Merck headquartered?

Merck is headquartered in Rahway, New Jersey, USA.

What percentage of Merck’s sales comes from the United States?

Approximately half of Merck's sales are generated in the United States.

What is Merck's approach to research and development?

Merck invests heavily in research and development with over 2,250 ongoing clinical trials. Their approach focuses on innovative treatments and combination regimens to address complex health challenges.

What recent achievements has Merck announced?

Merck recently surpassed its goal of reaching 25 million women with its maternal health initiative, Merck for Mothers, by reaching over 30 million women. Additionally, they have reported promising results from clinical trials involving KEYTRUDA.

Does Merck collaborate with other companies for research?

Yes, Merck is actively involved in numerous partnerships and collaborative research initiatives to accelerate the development of new therapies.

What is the historical origin of Merck & Co., Inc.?

Merck & Co., Inc. originated from the Merck Group, which was founded in Germany in 1668. The American arm, now an independent company, was established to serve the United States and Canada.

Stock MRK logo
Merck & Co., Inc.

NYSE:MRK

MRK Rankings

#35 Ranked by Market Cap
#946 Ranked by Dividends

MRK Stock Data

254.66B
2.53B
0.06%
79.47%
1.04%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
KENILWORTH